申请人:Celgene CAR LLC
公开号:US20170218353A1
公开(公告)日:2017-08-03
The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.